ES2075348T3 - Formulacion oral de serie polipeptida, disociable en el intestino grueso. - Google Patents

Formulacion oral de serie polipeptida, disociable en el intestino grueso.

Info

Publication number
ES2075348T3
ES2075348T3 ES91303560T ES91303560T ES2075348T3 ES 2075348 T3 ES2075348 T3 ES 2075348T3 ES 91303560 T ES91303560 T ES 91303560T ES 91303560 T ES91303560 T ES 91303560T ES 2075348 T3 ES2075348 T3 ES 2075348T3
Authority
ES
Spain
Prior art keywords
dissociable
large intestine
oral formulation
polypeptide
chitosan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91303560T
Other languages
English (en)
Inventor
Takeru Fujii
Shigeyuki Takama
Takahiko Watoh
Tsutomu Suzuki
Takayuki Matsumoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aicello Chemical Co Ltd
Original Assignee
Aicello Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicello Chemical Co Ltd filed Critical Aicello Chemical Co Ltd
Application granted granted Critical
Publication of ES2075348T3 publication Critical patent/ES2075348T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE OBTIENE UN MEDICAMENTO DE POLIPEPTIDO DISOCIADO DEL INTESTINO GRUESO FORMANDO UNA CAPA DE REVESTIMIENTO DE UN POLIMERO SOLUBLE EN UN LIQUIDO QUE TIENE UN PH DE AL MENOS 5 SOBRE LA SUPERFICIE DE UN MEDICAMENTO COMPUESTO DE UN QUITOSANO QUE CONTIENE UN POLIPEPTIDO FISIOLOGICAMENTE ACTIVO, UN MEDICAMENTO COMPUESTO FORMADO QUE REVISTE UN POLIPEPTIDO FISIOLOGICAMENTE ACTIVO CON QUITOSANO, O UN MEDICAMENTO COMPUESTO FORMADO QUE ENCAPSULA UN POLIPEPTIDO FISIOLOGICAMENTE ACTIVO CON UNA CAPSULA QUE CONTIENE QUITOSANO.
ES91303560T 1990-04-23 1991-04-22 Formulacion oral de serie polipeptida, disociable en el intestino grueso. Expired - Lifetime ES2075348T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP02107060 1990-04-23
JP3100304A JPH0813748B2 (ja) 1990-04-23 1991-04-05 大腸崩壊性ポリペプチド系経口製剤

Publications (1)

Publication Number Publication Date
ES2075348T3 true ES2075348T3 (es) 1995-10-01

Family

ID=26441356

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91303560T Expired - Lifetime ES2075348T3 (es) 1990-04-23 1991-04-22 Formulacion oral de serie polipeptida, disociable en el intestino grueso.

Country Status (8)

Country Link
EP (1) EP0454383B1 (es)
JP (1) JPH0813748B2 (es)
KR (1) KR100262202B1 (es)
AT (1) ATE124255T1 (es)
CA (1) CA2041044C (es)
DE (1) DE69110740T2 (es)
DK (1) DK0454383T3 (es)
ES (1) ES2075348T3 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH064531B2 (ja) * 1990-06-04 1994-01-19 アイセロ化学株式会社 大腸崩壊性硬質カプセル
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
DK0667148T3 (da) * 1992-11-06 2002-07-22 Hisamitsu Pharmaceutical Co Peroralt farmaceutisk præparat, der udløses i den nedre del af mavetarmkanalen
EP0759303B1 (en) * 1994-04-22 2002-10-16 Yamanouchi Pharmaceutical Co. Ltd. Colon-specific drug release system
EP0843559A2 (en) * 1996-06-11 1998-05-27 Zonagen, Inc. Chitosan drug delivery system
US6248362B1 (en) * 1997-03-26 2001-06-19 Meiji Seika Kaisha, Ltd. Large intestinal delivery composite
FI20000780A7 (fi) * 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
CL2008000905A1 (es) 2007-03-29 2008-08-22 Progenics Pharm Inc Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2010062261A1 (en) * 2008-11-29 2010-06-03 The Thailand Research Fund System and method for preparing a controlled releas preparation
JP5496616B2 (ja) * 2009-11-18 2014-05-21 フロイント産業株式会社 大腸ドラッグデリバリーシステム製剤
CN102552919B (zh) * 2010-12-15 2018-03-27 上海安博生物医药股份有限公司 一种给药组合物及其制备和使用方法
AU2010339907A1 (en) * 2009-12-16 2012-07-05 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
JP5102401B1 (ja) 2012-03-30 2012-12-19 森下仁丹株式会社 大腸特異崩壊性カプセル
ITUA20161937A1 (it) * 2016-03-23 2017-09-23 S I I T S R L Servizio Int Imballaggi Termosaldanti Preparazione per il controllo del peso corporeo a base di chitosano e cellulosa
CN115192537B (zh) * 2022-07-27 2024-03-26 康普药业股份有限公司 一种甲磺酸萘莫司他组合物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03500721A (ja) * 1987-07-24 1991-02-21 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン 半透膜内に生物学的材料のカプセル化

Also Published As

Publication number Publication date
DE69110740D1 (de) 1995-08-03
KR920005690A (ko) 1992-04-03
JPH04225922A (ja) 1992-08-14
DK0454383T3 (da) 1995-11-13
KR100262202B1 (ko) 2000-09-01
CA2041044A1 (en) 1991-10-24
EP0454383B1 (en) 1995-06-28
DE69110740T2 (de) 1995-11-23
ATE124255T1 (de) 1995-07-15
CA2041044C (en) 1996-03-26
EP0454383A1 (en) 1991-10-30
JPH0813748B2 (ja) 1996-02-14

Similar Documents

Publication Publication Date Title
ES2075348T3 (es) Formulacion oral de serie polipeptida, disociable en el intestino grueso.
DE69226950D1 (de) Kapsel mit Langzeitwirkung fuer die Adhäsion im Gastrointestinaltrakt
PT795324E (pt) Comprimido farmaceutico caracterizado por apresentar um elevado aumento volumerico quando colocado em contacto com fluidos biologicos
CA2221356A1 (en) Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
DE3686936D1 (de) Am zielorgan wirkendes enterales abgabesystem.
PT754452E (pt) Preparacoes farmaceuticas na forma de capsulas revestidas libertavel na parte inferior do tracto digestivo
AU7992987A (en) Method and formulation for orally administering bioactive agents to and through the peyer's patch
EP0256999A3 (en) Use of acetyl l-carnitine in the therapeutical treatment of peripheral neuropathies
ES2075468T3 (es) Vehiculos de suministro de farmacos suspendidos en un portador perfluorado no acuoso.
DE69637441D1 (de) Verabreichung unlöslicher arzneistoffe
CA2043841A1 (en) Large intestinal dissociative hard capsules
BG100933A (en) Polymer coated tablets comprising amoxycilin and clavulanate
CA2047738A1 (en) Dispensing device
DK0421921T3 (da) Dobbeltovertrukne granulater
CA2170748A1 (en) Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
BE874596A (fr) Medicament sous la forme d'une solution aqueuse sterile stable de cisplatine
FR2661910B1 (fr) Derives d'imino-2 heterocyclylalkyl-3 benzothiazoline, leur preparation et les medicaments les contenant.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 454383

Country of ref document: ES